Search

Your search keyword '"Lazzari, E"' showing total 370 results
Start Over Author "Lazzari, E"
370 results on '"Lazzari, E"'

3. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis

Author

Athan, E., Harris, O., Korman, T.M., Kotsanas, D., Jones, P., Reinbott, P., Ryan, S., Fortes, C.Q., Garcia, P., Jones, S.B., Barsic, B., Bukovski, S., Selton-Suty, C., Aissa, N., Doco-Lecompte, T., Delahaye, F., Vandenesch, F., Tattevin, P., Hoen, B., Plesiat, P., Giamarellou, H., Giannitsioti, E., Tarpatzi, E., Durante-Mangoni, E., Iossa, D., Orlando, S., Ursi, M.P., Pafundi, P.C., D' Amico, F., Bernardo, M., Cuccurullo, S., Dialetto, G., Covino, F.E., Manduca, S., Della Corte, A., De Feo, M., Tripodi, M.F., Baban, T., Kanafani, Z.A., Kanj, S.S., Sfeir, J., Yasmine, M., Morris, A., Murdoch, D.R., Premru, M.M., Lejko-Zupanc, T., Almela, M., Ambrosioni, J., Azqueta, M., Brunet, M., Cervera, C., De Lazzari, E., Falces, C., Fuster, D., Garcia-de-la-Mària, C., Garcia-Gonzalez, J., Gatell, J.M., Marco, F., Miró, J.M., Moreno, A., Ortiz, J., Ninot, S., Paré, J.C., Pericas, J.M., Quintana, E., Ramirez, J., Sandoval, E., Sitges, M., Tolosana, J.M., Vidal, B., Vila, J., Bouza, E., Muñoz, P., Rodríguez-Créixems, M., Ramallo, V., Bradley, S., Wray, D., Steed, L., Cantey, R., Peterson, G., Stancoven, A., Woods, C., Corey, G.R., Reller, L.B., Fowler, V.G., Jr., Chu, V.H., Baloch, K., Dixon, C.C., Harding, T., Jones-Richmond, M., Pappas, P., Park, L.P., Redick, T., Stafford, J., Anstrom, K., Bayer, A.S., Cabell, C.H., Karchmer, A.W., Sexton, D.J., Wang, A., Chu, V., Durack, D.T., Eykyn, S., Moreillon, P., Olaison, L., Raoult, D., Rubinstein, E., Pericàs, J.M., Messina, J.A., Park, L., Sharma-Kuinkel, B.K., and Carugati, M.

Published
2017
Full Text
View/download PDF

4. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study

Author

Laguno, M., Von Wichmann, M.A., Van den Eynde, E., Navarro, J., Cifuentes, C., Murillas, J., Veloso, S., Martínez-Rebollar, M., Guardiola, J.M., Jou, A., Gómez-Sirvent, J.L., Cervantes, M., Pineda, J.A., López-Calvo, S., Carrero, A., Montes, M.L., Deig, E., Tapiz, A., Ruiz-Mesa, J.D., Cruceta, A., de Lazzari, E., and Mallolas, J.

Published
2016
Full Text
View/download PDF

8. Chrysotile asbestos migration in air from contaminated water: An experimental simulation

Author

Avataneo C.[1, Petriglieri J.R.[2, Capella S.[1, Tomatis M.[2, Luiso M.[4], Marangoni G.[4], Lazzari E.[4], Tinazzi S.[5], Lasagna M.[1], De Luca D.A.[1], Bergamini M.[4], Belluso E.[1, 2, Turci F.[2, and 3

Subjects
Environmental Engineering, Balangero, Asbestos, Serpentine, Environmental fate, Health, Toxicology and Mutagenesis, Naturally occurring asbestos, Volume Unit, medicine.disease_cause, Dispersion (geology), World health, Asbestos, Occupational Exposure, Chrysotile, medicine, Environmental Chemistry, Humans, Waste Management and Disposal, Migration, Water, Contamination, naturally occurring asbestos, migration, simulation test, environmental fate, Pollution, Contaminated water, Italy, Environmental chemistry, Simulation test, Soil water, Environmental science
Abstract

In Naturally Occurring Asbestos (NOA) rich areas, water flows through asbestos bearing rocks and soils and generates waterborne fibres that may migrate in air and become a risk for humans. Research on the migration and dispersion after water vaporisation has been so far only marginally evaluated. This study investigates the migration in air of asbestos from a set of suspensions contaminated by chrysotile from Balangero (Italy), under controlled laboratory conditions. We evaluated i) the morphological modifications that might occur to chrysotile during migration from water to air, and ii) the amount of airborne chrysotile mobilised from standardised suspensions. Morphological alteration of asbestos fibres occurred during water-air migration and impacted on the analytical response of electron microscopy. Waterborne asbestos concentration higher than 40 ∙ 106 f/L generates in air concentration higher than 1 fibre per litre [f/L], the alarm threshold limit set by World Health Organization for airborne asbestos. A possible correlation between the waterborne fibre concentration as mass or number of fibres per volume unit [μg/L or f/L] was observed.

Published
2022
Full Text
View/download PDF

9. Projecting the contribution of assisted reproductive technology to completed cohort fertility

Author

Lazzari, E.

Abstract

Assisted reproductive technology (ART) is having an increasing influence on the fertility trends of high income countries characterised by a pattern of delayed childbearing. However, knowledge about the relationship between ART and completed fertility is limited and the extent to which delayed births are realized later in life through ART remains unexplored. Using data from Australian fertility clinics and national birth registries, the aim of this study is twofold: to project the contribution of ART for cohorts of women that have not yet completed their reproductive life; and to estimate the role played by ART in the fertility recuperation process. The proportion of children born after ART treatment is estimated to increase from 2.1% among women born in 1968 to 4.8-5.8% among women born in 1986. ART is projected to substantially affect the extent to which childbearing delay will be compensated at older ages, indicating that its availability may become an important factor in helping women to fulfil their reproductive plans later in life.

Published
2021

14. Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

Author

Palacio-Vieira, J, Reyes-Uruena, JM, Imaz, A, Bruguera, A, Force, L, Llaveria, AO, Llibre, JM, Vilaro, I, Borras, FH, Falco, V, Riera, M, Domingo, P, de Lazzari, E, Miro, JM, Casabona, J, Gurgui M., and Hernandez, J.

Subjects
Linkage, Cohort studies, HIV, Reengagement, Lost to follow-up
Abstract

Background Despite remarkable achievements in antiretroviral therapy (ART), losses to follow-up (LTFU) might prevent the long-term success of HIV treatment and might delay the achievement of the 90-90-90 objectives. This scoping review is aimed at the description and analysis of the strategies used in high-income countries to reengage LTFU in HIV care, their implementation and impact. Methods A scoping review was done following Arksey & O ' Malley's methodological framework and recommendations from Joanna Briggs Institute. Peer reviewed articles were searched for in Pubmed, Scopus and Web of Science; and grey literature was searched for in Google and other sources of information. Documents were charted according to the information presented on LTFU, the reengagement procedures used in HIV units in high-income countries, published during the last 15 years. In addition, bibliographies of chosen articles were reviewed for additional articles. Results Twenty-eight documents were finally included, over 80% of them published in the United States later than 2015. Database searches, phone calls and/or mail contacts were the most common strategies used to locate and track LTFU, while motivational interviews and strengths-based techniques were used most often during reengagement visits. Outcomes like tracing activities efficacy, rates of reengagement and viral load reduction were reported as outcome measures. Conclusions This review shows a recent and growing trend in developing and implementing patient reengagement strategies in HIV care. However, most of these strategies have been implemented in the United States and little information is available for other high-income countries. The procedures used to trace and contact LTFU are similar across reviewed studies, but their impact and sustainability are widely different depending on the country studied.

Published
2021

15. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial

Author

Rojas, J, de Lazzari, E, Negredo, E, Domingo, P, Tiraboschi, J, Ribera, E, Abdulghani, N, Puig, J, Mateo, MG, Podzamczer, D, Gutierrez, MM, Paredes, R, Clotet, B, Gatell, JM, Blanco, JL, Martinez, E, and DOLAM Study Grp

Abstract

Background Simplified antiretroviral therapy (ART) regimens are desirable for people with HIV. We investigated the efficacy and safety of switching from triple ART to dual dolutegravir plus lamivudine therapy. Methods DOLAM is a phase 4, randomised, open-label, non-inferiority trial, done at six HIV clinics in Catalonia, Spain. Adults with HIV-1 receiving a triple ART regimen, aged 18 years or older, with virological suppression, a CD4 nadir of at least 200 cells per ILL, who were HBsAg-negative, and without previous viral failure or resistance mutations to study drugs were eligible. Participants underwent computer-generated randomisation, stratified by the class of the third drug, and were assigned (1:1) to switch to oral dolutegravir 50 mg and lamivudine 300 mg once daily or to continue triple ART for 48 weeks. The primary endpoint was the proportion of people with an HIV RNA value of at least 50 copies per mL at week 48 (US Food and Drug Administration snapshot algorithm, 8% non-inferiority margin). Both the primary and safety outcomes were evaluated in the intention-to-treat exposed population. The study is completed and was registered with EudraCT 201500027435. Findings Between July 7, 2015, and Oct 31, 2018, 265 participants were randomly assigned to switch to dolutegravir plus lamivudine (n=131) or to maintain triple ART (n=134) and all received at least one dose. Nine (7%) participants in the dual therapy group and ten (7%) in the triple therapy group were excluded before 48 weeks, mostly due to treatment discontinuations or virological failure. Participants were predominantly male (116 [87%] of 134 in the triple ART group and 111 [85%] of 131 in the dolutegravir plus lamivudine group). The difference in the proportion of participants with HIV RNA values of at least 50 copies per mL at 48 weeks between the dual therapy group (three [2%] of 131) and triple therapy group (two [1%] of 134) was 0middot8 percentage points (95% CI -3middot3 to 5middot2), showing non-inferiority of dolutegravir plus lamivudine dual therapy compared with triple ART. 73 (56%) of 131 participants allocated to dual therapy had 150 adverse effects, compared with 78 (58%) of 134 participants allocated to triple therapy who also had 150 adverse events (p=0middot68). Drug discontinuation due to adverse effects occurred in four people in the triple therapy group and three people in the dual therapy group. Interpretation Our findings show the efficacy and safety of dolutegravir plus lamivudine as a simplified therapy switch option for selected people with HIV with virological suppression on triple ART.

Published
2021

20. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

Author

Beltrán-Pavez, C., Gutiérrez-López, M., Rubio-Garrido, M., Valadés-Alcaraz, A., Prieto, L., Ramos, J.T., Jiménez De Ory, S., Navarro, M., Díez-Romero, C., Pulido, F., Valencia, E., Holguín, Á., Mellado, M.J., Escosa, L., García Hortelano, M., Sainz, T., González-Tomé, M.I., Rojo, P., Blázquez, D., Prieto-Tato, L., Epalza, C., Guillén, S., Navarro, M.L., Saavedra, J., Santos, M., Santiago, B., Aguilera-Alonso, D., Carrasco, I., Roa, M.Á., Penín, M., Martínez, J., Badillo, K., Oñate, E., Pocheville, I., Garrote, E., Colino, E., Gómez Sirvent, J., Garzón, M., Román, V., Angulo, R., Neth, O., Falcón, L., Terol, P., Santos, J.L., Moreno, D., Lendínez, F., Peromingo, E., Uberos, J., Ruiz, B., Grande, A., Romero, F.J., Pérez, C., Lillo, M., Losada, B., Herranz, M., Bustillo, M., Collado, P., Couceiro, J.A., Vila, L., Calviño, C., Piqueras, A.I., Oltra, M., Gavilán, C., Montesinos, E., Dapena, M., Álvarez, C., Jiménez, B., Andrés, A.G., Marugán, V., Ochoa, C., Alfayate, S., Menasalvas, A.I., Ruiz Del Prado, Y., Soler-Palacín, P., Frick, M.A., Mur, A., López, N., Méndez, M., Mayol, L., Vallmanya, T., Calavia, O., García, L., Coll, M.T., Pineda, V., Rius, N., Dueñas, J., Fortuny, C., Noguera-Julián, A., Bernardino, I., Montes, M.L., Rubio, R., Bisbal, O., Gaspar Alonso, G., Berenguer, J., Díez, C., Aldamiz, T., Montilla, P., Bermúdez, E., Valerio, M., Sanz, J., Arponen, S., Gimeno, A., Cervero, M., Torres, R., Moreno, S., Pérez, M.ªJ., Ryan, P., Troya, J., Losa, J., Gómez, R., Iribarren, J.A., Rodríguez, F., Pascual, L., Aramburu, M.J., Goikoetxea, A.J., Aguirrebengoa, L., Muñoz, J., Ibarra, S., Hernández, M., Gómez Sirvent, J.L., Rodríguez, J., Cárdenes, M.Á., López-Cortés, L.F., Roca, C., Llaves, S., Ríos, M.J., Palomo, V., Pasquau, J., García, C., Hernández, J., Martínez, C., Rivero, A., Camacho, Á., Merino, D., Martínez, E., Mateos, F., Blanch, J.J., Torralba, M., Arazo, P., Samperiz, G., Crusells, M.J., San Joaquín, I., Miralles, C., Ocampo, A., Pousada, G., Mena, Á., Montero, M., Salavert, M., Cuéllar, S., Galindo, M.J., Ferrando, R., Portilla, J., Portilla, I., Gutiérrez, F., Masiá, M., Robledano, C., Adsuar, A., Hinojosa, C., Bachiller, P., Abadía, J., Mostaza, J.L., Pérez, R., Galera, C., Albendín, H., Pérez, A., Blanco, J.R., Burgos, J., Torres, B., and Lazzari, E.

Abstract

The aim of this transversal study was to describe the virological and immunological features of HIV-infected youths transferred from pediatric to adult care units since 1997 vs. the non-transferred patients from the Madrid Cohort of HIV-infected children and adolescents in Spain. We included 106 non-transferred and 184 transferred patients under clinical follow-up in 17 public hospitals in Madrid by the end of December 2017. Virological and immunological outcomes were compared in transferred vs. non-transferred patients. ART drug resistance mutations and HIV-variants were analyzed in all subjects with available resistance pol genotypes and/or genotypic resistance profiles. Among the study cohort, 133 (72.3%) of 184 transferred and 75 (70.7%) of 106 non-transferred patients had available resistance genotypes. Most (88.9%) of transferred had ART experience at sampling. A third (33.3%) had had a triple-class experience. Acquired drug resistance (ADR) prevalence was significantly higher in pretreated transferred than non-transferred patients (71.8% vs. 44%; p = 0.0009), mainly to NRTI (72.8% vs. 31.1%; p < 0.0001) and PI (29.1% vs. 12%; p = 0.0262). HIV-1 non-B variants were less frequent in transferred vs. non-transferred (6.9% vs. 32%; p < 0.0001). In conclusion, the frequent resistant genotypes found in transferred youths justifies the reinforcement of HIV resistance monitoring after the transition to avoid future therapeutic failures.

Published
2020

24. Intrathoracic fat in HIV-infected patients

Author

Blanco, J L, Biglia, A, Martinez, E, Sánchez, M, de Lazzari, E, Leon, A, Milinkovic, A, Larrousse, M, Lonca, M, Laguno, M, Mallolas, J, and Gatell, J M

Published
2006

26. Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response

Author

Revell, AD, Wang, DC, Reiss, P, van Sighem, AI, Montaner, JSG, Larder, BA, Harrigan, R, de Wit, TR, Hamers, R, Sigaloff, K, Agan, B, Marconi, V, Wegner, S, Sugiura, W, Zazzi, M, Kaiser, R, Schuelter, E, Streinu-Cercel, A, Bals, M, Alvarez-Uria, G, de Oliveira, T, Lazzari, E, Gazzard, B, Nelson, M, Pozniak, A, Mandalia, S, Smith, C, Ruiz, L, Clotet, B, Staszewski, S, Lane, HC, Julia, A, Metcalf, Rehm, CA, Perez-Elias, MJ, Vella, S, Dettorre, G, Carr, A, Norris, R, Hesse, K, Vlahakis, E, Tempelman, H, Barth, R, Wood, R, Morrow, C, Cogill, D, Hoffmann, C, Ene, L, Dragovic, G, Diaz, R, Sucupira, C, Sued, O, Cesar, C, Madero, JS, Balakrishnan, P, Saravanan, S, Cooper, D, Torti, C, Baxter, J, Monno, L, Gatell, J, Picchio, G, deBethune, MP, Emery, S, Khabo, P, and Ledwaba, L

Subjects
machine learning, antiretroviral therapy, HIV/AIDS, treatment response, data mining, viral load
Abstract

Objective: Definitions of virological response vary from

Published
2019

27. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort

Author

Montoliu, A, Miro, JM, Domingo, P, Riera, M, Curran, A, Homar, F, Ambrosioni, J, Abdulghani, N, Force, L, Peraire, J, Vilaro, J, Masabeu, A, Orti, AJ, Dalmau, D, Casabona, J, Reyes, J, Bruguera, A, Muntada, E, Podzamczer, D, Llibre, JM, Navarro, G, Cortes, C, Falco, V, Mallolas, J, Manzardo, C, Imaz, A, Tiraboschi, J, Burgos, J, Mateo, MG, Gutierrez, MM, Murillas, J, Segura, F, Garcia-Gasalla, M, Puig, T, Vidal, F, Leon, E, Jaen, A, Almuedo, A, De Lazzari, E, Giralt, D, Martin, M, Gargoulas, F, Vanrell, T, Rubia, JC, Vila, J, Ferres, M, Morell, B, Tamayo, M, Laguno, M, Martinez, M, Blanco, JL, Garcia-Alcaide, F, Rojas, J, Martinez, E, Jou, A, Clotet, B, Saumoy, M, Silva, A, Prieto, P, Ribera, JNIE, Gurgui, M, Campins, AA, Fanjul, FJ, Leyes, M, Penaranda, M, Martin, L, Vilchez, H, Calzado, S, Cervantes, M, Amengual, MJ, Navarro, M, Payeras, T, Cifuentes, C, Comella, T, Vargas, M, Vilades, C, Barrufet, P, Chivite, I, Chamarro, E, Escrig, C, Cairo, M, Martinez-Lacasa, X, Font, R, Deig, E, Meyer, S, and Hernandez, J

Subjects
integrase strand transfer inhibitors, elvitegravir/cobicistat, neuropsychiatric toxicity, raltegravir, adverse events, dolutegravir
Abstract

Objectives The aim of the study was to assess the rates of discontinuation of integrase inhibitor regimens because of any neuropsychiatric adverse event (NPAE) and the factors associated with discontinuation. Methods A population-based, prospective, multicentre cohort study was carried out. Treatment-naive subjects starting therapy with a regimen containing integrase inhibitors, or those switching to such a regimen, with plasma HIV-1 RNA < 50 HIV-1 RNA copies/mL in 14 hospitals in Catalonia or the Balearic Islands (Spain) were included in the study. Every discontinuation because of adverse events (AEs) was double-checked directly with treating physicians. Multivariable Cox models identified factors correlated with discontinuation. Results A total of 4165 subjects (37% treatment-naive) started regimens containing dolutegravir (n = 1650; 91% with abacavir), raltegravir (n = 930) or elvitegravir/cobicistat (n = 1585). There were no significant differences among regimens in the rate of discontinuation because of any AE. Rates of discontinuation because of NPAEs were low but higher for dolutegravir/abacavir/lamivudine [2.1%; 2.9 (95% confidence interval (CI) 2.0, 4.2) discontinuations/100 patients/year] versus elvitegravir/cobicistat (0.5%; 0.8 (95% CI 0.3, 1.5) discontinuations/100 patients/year], with significant differences among centres for dolutegravir/abacavir/lamivudine and NPAEs (P = 0.003). We identified an association of female gender and lower CD4 count with increased risk of discontinuation because of any AE [Incidence ratio (IR) 2.3 (95% CI 1.4, 4.0) and 1.8 (95% CI 1.1, 2.8), respectively]. Female gender, age > 60 years and abacavir use were not associated with NPAE discontinuations. NPAEs were commonly grade 1-2, and had been present before and improved after drug withdrawal. Conclusions In this large prospective cohort study, patients receiving dolutegravir, raltegravir or elvitegravir/cobicistat did not show significant differences in the rate of discontinuation because of any toxicity. The rate of discontinuations because of NPAEs was low, but was significantly higher for dolutegravir than for elvitegravir/cobicistat, with significant differences among centres, suggesting that greater predisposition to believe that a given adverse event is caused by a given drug of some treating physicians might play a role in the discordance seen between cohorts.

Published
2019

28. Determinants and Outcomes of Late Presentation of HIV Infection in Migrants in Catalonia, Spain: PISCIS Cohort 2004-2016

Author

Conway, AS, Esteve, A, Fernandez-Quevedo, M, Casabona, J, Miro, JM, Riera, AB, Montoliu, A, Reyes, J, Muntada, E, Bruguera, A, Podzamczer, D, Domingo, P, Llibre, JM, Riera, S, Navarro, G, Cortes, C, Falco, V, Gatell, JM, Manzardo, C, Clotet, B, Ferrer, E, Segura, F, Force, L, Vilaro, J, Masabeu, A, Leon, E, Cifuentes, C, Homar, F, Dalmau, D, Jaen, A, Mateo, MG, Gutierrez, MD, Loureiro, E, Curran, A, Puig, T, Agusti, C, Vidal, F, Peraire, J, Orti, A, Almuedo, A, De Lazzari, E, Giralt, D, Gargoulas, F, Rubia, JC, Vila, J, Ambrosioni, J, Zamora, L, Blanco, JL, Garcia-Alcaide, F, Martinez, E, Mallolas, J, Sirera, G, Romeu, J, Jou, A, Negredo, E, Saumoy, M, Imaz, A, Bolao, F, Cabellos, C, Pena, C, DiYacovo, S, Van Den Eynde, E, Sala, M, Cervantes, M, Amengual, MJ, Navarro, M, Segura, V, Barrufet, P, Payeras, T, Gurgui, M, Utrillo, L, Meyer, S, and Hernandez, J

Subjects
Migrant health, Spain, Cohort, HIV, HIV inequalities, Late presentation with HIV
Abstract

This study using the Catalan PISCIS cohort explores risk factors of migrants' late presentation and the impact of late presentation on their health outcomes. We analyse 9590 new HIV diagnoses enrolled in the cohort between 2004 and 2016. Univariate and multivariate logistic regression models are used to identify risk factors associated with late presentation among migrants, giving crude and adjusted odds ratios and their 95% confidence intervals. Cox regression models are estimated to identify risk factors associated with AIDS/death, and crude and adjusted hazard ratios and 95% confidence intervals are reported. Late presentation is higher in migrants than non-migrants. Among migrants, region of origin is associated with late presentation and AIDS/death during follow-up. The results highlight persisting inequalities in HIV diagnosis and care among migrants in Catalonia. Targeted interventions addressed to specific subgroups in the migrant population are needed.

Published
2019

30. Network meta‐analysis of post‐exposure prophylaxis randomized clinical trials.

Author

Fernández, I, Lazzari, E., Inciarte, A., Diaz‐Brito, V., Milinkovic, A., Arenas‐Pinto, A., Etcheverrry, F., García, F., Leal, L, Fernandez, E, Gonzalez, E, Lucero, C, Leon, A, Garcıa, F, Manzardo, C, Nicolas, D, Bodro, M, del Rıo, A, Cardozo, C, and Cervera, C

Subjects
*HIV prevention, *MEDLINE, *META-analysis, *ONLINE information services, *SYSTEMATIC reviews, *ANTIRETROVIRAL agents, *RANDOMIZED controlled trials, *TREATMENT effectiveness, *MEN who have sex with men, *ATAZANAVIR, *LOPINAVIR-ritonavir, *MARAVIROC (Drug), *RALTEGRAVIR, *HIV integrase inhibitors
Abstract

Objectives: We performed a network meta‐analysis of PEP randomized clinical trials to evaluate the best regimen. Methods: After MEDLINE/Pubmed search, studies were included if: (1) were randomized, (2) comparing at least 2 PEP three‐drug regimens and, (3) reported completion rates or discontinuation at 28 days. Five studies with 1105 PEP initiations were included and compared ritonavir‐boosted lopinavir (LPV/r) vs. atazanavir (ATV) (one study), cobicistat‐boosted elvitegravir (EVG/c) (one study), raltegravir (RAL) (one study) or maraviroc (MVC) (two studies). We estimated the probability of each treatment of being the best based on the evaluation of five outcomes: PEP non‐completion at day 28, PEP discontinuation due to adverse events, PEP switching due to any cause, lost to follow‐up and adverse events. Results: Participants were mostly men who have sex with men (n = 832, 75%) with non‐occupational exposure to HIV (89.86%). Four‐hundred fifty‐four (41%) participants failed to complete their PEP course for any reason. The Odds Ratio (OR) for PEP non‐completion at day 28 in each antiretroviral compared to LPV/r was: ATV 0.95 (95% CI 0.58–1.56; EVG/c: OR 0.65 95% CI 0.30–1.37; RAL: OR 0.68 95% CI 0.41–1.13; and MVC: OR 0.69 95% CI 0.47–1.01. In addition, the rankogram showed that EVG/c had the highest probability of being the best treatment for the lowest rates in PEP non‐completion at day 28, switching, lost to follow‐up or adverse events and MVC for PEP discontinuations due to adverse events. Conclusions: Our study shows the advantages of integrase inhibitors when used as PEP, particularly EVG as a Single‐Tablet Regimen. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

Author

Blanco, JL, Rojas, J, Paredes, R, Negredo, E, Mallolas, J, Casadella, M, Clotet, B, Gatell, JM, de Lazzari, E, and Martinez, E

Abstract

Background: No controlled comparisons between dolutegravir/lamivudine or dolutegravir maintenance therapy have been done. We hypothesized that these options would have similar efficacy to triple ART. Methods: We used an open-label non-inferiority randomized controlled trial comprising two phases: phase A was established to test that experimental arms did not have an unacceptable (>= 5%) failure rate; phase B was intended to include the full number of patients followed for 48 weeks. Treated HIV-1-infected adults with viral load,50 copies/mL for >= 12months, no prior viral failure or resistance mutations to study drugs, nadir CD4.200 cells/mm(3), and hepatitis B virus surface antigen negative were randomized 1: 1: 1 to maintain triple therapy (control arm), or to switch to dolutegravir/lamivudine, or to dolutegravir monotherapy stratifying by anchor drug. Premature discontinuation was considered if viral failure or therapy interruption due to adverse events, concurrent illness, protocol deviation or patient's wish occurred. Blips were registered. Planned phase A results at 24 weeks are reported here. The study is registered at EudraCT: 201500027435. Results: Ninety-one (control, n = 31; dual therapy, n = 29; monotherapy, n = 31) patients were randomized. Three patients (none previously exposed to integrase inhibitors) prematurely discontinued treatment due to viral failure: dolutegravir/lamivudine (n = 1), no resistance mutations (subject A); dolutegravir (n = 2), N155H, S147G and Q148R resistance mutations (subject B), and E138K, G140S and N155H resistance mutations (subject C). There were no discontinuations for other reasons. One patient (dolutegravir/lamivudine) experienced a blip in viral load. The Data Safety Monitoring Board recommended stopping the dolutegravir monotherapy arm. Conclusions: In contrast to dolutegravir/lamivudine, a higher than expected risk of viral failure with development of cross-resistance integrase mutations occurred with dolutegravir maintenance monotherapy.

Published
2018

33. Influence of Vancomycin Minimum Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus Left-Sided Infective Endocarditis Treated with Anti-staphylococcal Beta-Lactam Antibiotics; a Prospective Cohort Study by the International Collaboration on Endocarditis

Author

Athan, E., Harris, O., Korman, T. M., Kotsanas, D., Jones, P., Reinbott, P., Ryan, S., Fortes, C. Q., Garcia, P., Jones, S. B., Barsic, B., Bukovski, S., Selton-Suty, C., Aissa, N., Doco-Lecompte, T., Delahaye, F., Vandenesch, F., Tattevin, P., Hoen, B., Plesiat, P., Giamarellou, H., Giannitsioti, E., Tarpatzi, E., Durante-Mangoni, E., Iossa, D., Orlando, S., Ursi, M. P., Pafundi, P. C., D' Amico, F., Bernardo, M., Cuccurullo, S., Dialetto, G., Covino, F. E., Manduca, S., Della Corte, A., De Feo, M., Tripodi, M. F., Baban, T., Kanafani, Z. A., Kanj, S. S., Sfeir, J., Yasmine, M., Morris, A., Murdoch, D. R., Premru, M. M., Lejko-Zupanc, T., Almela, M., Ambrosioni, J., Azqueta, M., Brunet, M., Cervera, C., De Lazzari, E., Falces, C., Fuster, D., Garcia-de-la-Maria, C., Garcia-Gonzalez, J., Gatell, J. M., Marco, F., Miro, J. M., Moreno, A., Ortiz, J., Ninot, S., Pare, J. C., Pericas, J. M., Quintana, E., Ramirez, J., Sandoval, E., Sitges, M., Tolosana, J. M., Vidal, B., Vila, J., Bouza, E., Rodriguez-Creixems, M., Ramallo, V., Bradley, S., Wray, D., Steed, L., Cantey, R., Peterson, G., Stancoven, A., Woods, C., Corey, G. R., Reller, L. B., Fowler, V. G., Chu, V. H., Messina, J. A., Park, L., Sharma-Kuinkel, B. K., Carugati, M., Munoz, P., Baloch, K., Dixon, C. C., Harding, T., Jones-Richmond, M., Pappas, P., Park, L. P., Redick, T., Stafford, J., Anstrom, K., Bayer, A. S., Cabell, C. H., Karchmer, A. W., Sexton, D. J., Wang, A., Chu, V., Durack, D. T., Eykyn, S., Moreillon, P., Olaison, L., Raoult, D., Rubinstein, E., Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Duke University Medical Center, University of Barcelona, Medical University of South Carolina [Charleston] (MUSC), American University of Beirut [Beyrouth] (AUB), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Université de Tsukuba = University of Tsukuba, Pericàs, J M, Messina, J A, Garcia-de-la-Mària, C, Park, L, Sharma-Kuinkel, B K, Marco, F, Wray, D, Kanafani, Z A, Carugati, M, Durante Mangoni, E, Tattevin, P, Chu, V H, Moreno, A, Fowler, V G, Miró, J M, De Feo, Marisa, Athan, E11, Harris, O11, Korman, Tm12, Kotsanas, D13, Jones, P14, Reinbott, P14, Ryan, S14, Fortes, Cq15, Garcia, P16, Jones, Sb16, Barsic, B17, Bukovski, S17, Selton-Suty, C18, Aissa, N18, Doco-Lecompte, T18, Delahaye, F19, Vandenesch, F19, Tattevin, P20, Hoen, B21, Plesiat, P21, Giamarellou, H22, Giannitsioti, E22, Tarpatzi, E22, Durante-Mangoni, E23, Iossa, D23, Orlando, S23, Ursi, Mp23, Pafundi, Pc23, D' Amico, F23, Bernardo, M23, Cuccurullo, S23, Dialetto, G23, Covino, Fe23, Manduca, S23, DELLA CORTE, Alessandro, De Feo, M23, Tripodi, Mf24, Baban, T25, Kanafani, Za25, Kanj, Ss25, Sfeir, J25, Yasmine, M25, Morris, A26, Murdoch, Dr27, Premru, Mm28, Lejko-Zupanc, T28, Almela, M29, Ambrosioni, J29, Azqueta, M29, Brunet, M29, Cervera, C29, De Lazzari, E29, Falces, C29, Fuster, D29, Garcia-de-la-Mària, C29, Garcia-Gonzalez, J29, Gatell, Jm29, Marco, F29, Miró, Jm29, Moreno, A29, Ortiz, J29, Ninot, S29, Paré, Jc29, Pericas, Jm29, Quintana, E29, Ramirez, J29, Sandoval, E29, Sitges, M29, Tolosana, Jm29, Vidal, B29, Vila, J29, Bouza, E30, Muñoz, P, Rodríguez-Créixems, M30, Ramallo, V30, Bradley, S31, Wray, D32, Steed, L32, Cantey, R32, Peterson, G33, Stancoven, A33, Woods, C34, Corey, Gr34, Reller, Lb34, Fowler VG, Jr34, Chu, Vh34, Baloch, K, Chu, Vh, Corey, Gr, Dixon, Cc, Fowler VG, Jr, Harding, T, Jones-Richmond, M, Pappas, P, Park, Lp, Redick, T, Stafford, J, Anstrom, K, Athan, E, Bayer, A, Cabell, Ch, Hoen, B, Karchmer, Aw, Miró, Jm, Murdoch, Dr, Sexton, Dj, Wang, A, Chu, V, Durack, Dt, Eykyn, S, Moreillon, P, Olaison, L, Raoult, D, Rubinstein, E, and Sexton, Dj.

Subjects
0301 basic medicine, Male, medicine.disease_cause, 0302 clinical medicine, 80 and over, Medicaments antibacterians, 030212 general & internal medicine, Endocarditi, Prospective Studies, Aged, 80 and over, Endocarditis, Bacterial, General Medicine, Middle Aged, Staphylococcal Infections, 3. Good health, Anti-Bacterial Agents, Fenotip, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Treatment Outcome, Phenotype, Staphylococcus aureus, Infective endocarditis, Staphylococcus aureu, Vancomycin, Genotype, Vancomycin MIC, Adult, Aged, Endocarditis, Bacterial, Female, Humans, Microbial Sensitivity Tests, Molecular Typing, Multiplex Polymerase Chain Reaction, Survival Analysis, Virulence Factors, beta-Lactams, medicine.drug, Microbiology (medical), 030106 microbiology, Biology, Staphylococcal infections, Article, Microbiology, 03 medical and health sciences, Minimum inhibitory concentration, medicine, Etest, Endocarditis Staphylococcus aureus, biochemical phenomena, metabolism, and nutrition, medicine.disease, Antibacterial agents, Methicillin Susceptible Staphylococcus Aureus
Abstract

Objectives: Left-sided methicillin-susceptible Staphylococcus aureus (MSSA) endocarditis treated with cloxacillin has a poorer prognosis when the vancomycin minimum inhibitory concentration (MIC) is >= 1.5 mg/L. We aimed to validate this using the International Collaboration on Endocarditis cohort and to analyse whether specific genetic characteristics were associated with a high vancomycin MIC (> 1.5mg/L) phenotype.Methods: All patients with left-sided MSSA infective endocarditis treated with antistaphylococcal beta-lactam antibiotics between 2000 and 2006 with available isolates were included. Vancomycin MIC was determined by Etest as either high (>= 1.5 mg/L) or low (

Published
2017
Full Text
View/download PDF

35. An update to the HIV-TRePS system: The development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype

Author

Revell, A. D., Wang, D., Wood, R., Morrow, C., Tempelman, H., Hamers, R. L., Reiss, P., van Sighem, A. I., Nelson, M., Montaner, J. S. G., Lane, H. C., Larder, B. A., Harrigan, R., de Wit, T. R., Hamers, R., Sigaloff, K., Agan, B., Marconi, V., Wegner, S., Sugiura, W., Zazzi, M., Kaiser, R., Schuelter, E., Streinu-Cercel, A., Alvarez-Uria, G., Gatell, J., Lazzari, E., Gazzard, B., Pozniak, A., Mandalia, S., Webster, D., Smith, C., Ruiz, L., Clotet, B., Staszewski, S., Torti, C., Lane, C., Metcalf, J., Perez-Elias, M. -J., Vella, S., Dettorre, G., Carr, A., Norris, R., Hesse, K., Vlahakis, E., Barth, R., Hoffmann, C., Ene, L., Dragovic, G., Diaz, R., Sucupira, C., Sued, O., Cesar, C., Madero, J. S., Emery, S., Cooper, D., Baxter, J., Monno, L., Picchio, G., Debethune, M. -P., Khabo, P., Ledwaba, L., Global Health, Infectious diseases, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, and Internal medicine

Subjects
0301 basic medicine, Microbiology (medical), Genotype, Anti-HIV Agents, 030106 microbiology, Human immunodeficiency virus (HIV), Antiretroviral Therapy, HIV Infections, Biology, medicine.disease_cause, Bioinformatics, Algorithms, Health Resources, Humans, Models, Statistical, ROC Curve, Software, South Africa, Treatment Outcome, Viral Load, Antiretroviral Therapy, Highly Active, Computer Simulation, 03 medical and health sciences, 0302 clinical medicine, Models, Statistics, medicine, Pharmacology (medical), Highly Active, 030212 general & internal medicine, Hiv treatment, Genotyping, Original Research, Pharmacology, Computational model, Statistical, Random forest, Regimen, Infectious Diseases, Test set
Abstract

Objectives: Optimizing antiretroviral drug combination on an individual basis in resource-limited settings is challenging because of the limited availability of drugs and genotypic resistance testing. Here, we describe our latest computational models to predict treatment responses, with or without a genotype, and compare the potential utility of global and local models as a treatment tool for South Africa. Methods: Global random forest models were trained to predict the probability of virological response to therapy following virological failure using 29 574 treatment change episodes (TCEs) without a genotype, 3179 of which were from South Africa and were used to develop local models. In addition, 15 130 TCEs including genotypes were used to develop another set of models. The 'no-genotype' models were tested with an independent global test set (n = 1700) plus a subset from South Africa (n = 222). The genotype models were tested with 750 independent cases. Results: The global no-genotype models achieved area under the receiver-operating characteristic curve (AUC) values of 0.82 and 0.79 with the global and South African tests sets, respectively, and the South African models achieved AUCs of 0.70 and 0.79. The genotype models achieved an AUC of 0.84. The global no-genotype models identified more alternative, locally available regimens that were predicted to be effective for cases that failed their new regimen in the South African clinics than the local models. Both sets of models were significantly more accurate predictors of outcomes than genotyping with rules-based interpretation. Conclusions: These latest global models predict treatment responses accurately even without a genotype, out-performed the local South African models and have the potential to help optimize therapy, particularly in resource-limited settings.

Published
2016
Full Text
View/download PDF

36. Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study

Author

Aga¼ero, F., Rimola, A., Stock, P., Grossi, P., Rockstroh, J. K., Agarwal, K., Garzoni, C., Barcan, L. A., Maltez, F., Manzardo, C., Mari, M., Ragni, M. V., Anadol, E., Di Benedetto, F., Nishida, S., Gastaca, M., Mira, J. M., Pedreira, J. D., Castro, M. A., Lapez, S., Sua¡rez, F., Vazquez, P., Blanch, J., Brunet, M., Cervera, C., de Lazzari, E., Fondevila, C., Forner, A., Fuster, J., Freixa, N., GarcA­a-Valdecasas, J. C., Gil, A., Gatell, J. M., Laguno, M., Marta­nez, M., Mallolas, J., Monras, M., Moreno, A., Murillas, J., Paredes, D., Pacopyrightrez, I., Torres, F., Tural, C., Tuset, M., Antela, A., Fernandez, J., Losada, E., Varo, E., Lozano, R., Araiz, J. J., Barrao, E., Letona, S., Luque, P., Navarro, A., Sanjoaqua­n, I., Serrano, T., Tejero, E., Salcedo, M., BaA+/-ares, R., Calleja, J., Berenguer, J., Cosa­n, J., Gutiacopyrightrrez, I., Lapez, J. C., Miralles, P., Rama­rez, M., Rincan, D., Sanchez, M., Jimacopyrightnez, M., de la Cruz, J., Ferna¡ndez, J. L., Lozano, J. M., Santoyo, J., Rodrigo, J. M., Sua¡rez, M. A., Rodra­guez, M., Alonso, M. P., Asensi, V., Gonza¡lez, M. L., GonzA¡lez-Pinto, I., Rafecas, A., Carratala¡, J., Fabregat, J., Ferna¡ndez, N., Xiol, X., Montejo, M., Bustamante, J., Ferna¡ndez, J. R., Montejo, E., Ortiz de Urbina, J., Ruiz, P., Sua¡rez, M. J., Testillano, M., Valdivieso, A., Ventoso, A., Abradelo, M., Costa, J. R., Fundora, Y., Jimacopyrightnez, S., Meneu, J. C., Moreno, E., Moreno, V., Olivares, S. P., Pacopyrightrez, B., Pulido, F., Rubio, R., Blanes, M., Aguilera, V., Berenguer, M., Lapez, J., Lapez, R., Prieto, M., FariA+/-as, M. C., Arnaiz, A., Casafont, F., Echevarria, S., Fa¡brega, E., Garca­a, J. D., Gamez, M., Gutiacopyrightrrez, J. M., Peralta, F. G., Teira, R., Moreno, S., Barcena, R., Del Campo, S., Fortaºn, J., Moreno, A. M., Torre-Cisneros, J., Barrera, P., Camacho, A., Cantisa¡n, S., Castan, J. J., de la Mata, M., Lara, M. R., Natera, C., Rivero, A., Vidal, E., Castells, L. I., Charco, R., Esteban, J. I., Gavalda¡, J., Len, O., Pahissa, A., Ribera, E., Vargas, V., Pons, J. A., Cordero, E., Bernal, C., Cisneros, J. M., Gamez, M. A., Pascasio, J. M., Rodra­guez, M. J., Sayazo, M., Sousa, J. M., Sua¡rez, G., Gonza¡lez, J., Aznar, E., Barquilla, E., Esteban, H., Krahe, L., Moyano, B., de la Rosa, G., Mahillo, B., Roland, M., Ascher, N., Roberts, J., Freise, C., Terrault, N., Carlson, L., Beatty, G., Chin-Hong, P., Dove, L., Emond, J., Lobritto, S., Neu, N., Yin, M., Kumar, A., Ringe, B., Jacobson, J., Sass, D., Diego, J., Tzakis, A., Roth, D., Schiff, E., Burke, G., Jayaweera, D., Olthoff, K., Blumberg, E., Bloom, R., Reddy, R., Ragni, M., Shapiro, R., De Vera, M. E., Shakil, O., Simon, D., Cohen, S. M., Dodson, S. F., Jensik, S., Saltzberg, S., Stosor, T., Green, R., Baker, T., Gallon, L., Scarsi, K., Hanto, D., Wong, M., Curry, M., Johnson, S., Pavlakis, M., Barin, B., Risaliti, A., Ancarani, F., Pinna, A. D., Morelli, C., Guaraldi, G., Tarantino, G., Baccarani, U., Tavio, M., Nanni Costa, A., Beckebaum, S., Radecke, K., Bickel, M., Sterneck, M., Zoufaly, A., Ganten, T., Stoll, M., Salzberger, B., Berg, C., Kittner, J., O'Grady, J., Joshi, D., Heaton, N., Smud, A., Genoud, N., Cahn, F., Valledor, A., Gadano, A., Barcan, L., Cusini, A., Rauch, A., Furrer, H., Ma¼ller, N. J., Khanna, N., van Delden, C., Oriol, M., Manata, M. J., Correia, F., Machado, J., Morbey, A., Glaria, H., Veloso, J., Perdigoto, R., Pereira, P., Martins, A., and Barroso, E.

Subjects
Male, medicine.medical_treatment, HCC INF, HIV Infections, Hepacivirus, 030230 surgery, Liver transplantation, medicine.disease_cause, Gastroenterology, Cohort Studies, 0302 clinical medicine, Postoperative Complications, Risk Factors, Adult, Coinfection, Female, Follow-Up Studies, Graft Survival, HIV-1, Hepatitis B, Hepatitis B virus, Hepatitis C, Humans, International Agencies, Middle Aged, Prognosis, Reoperation, Survival Rate, Liver Transplantation, Immunology and Allergy, Transplantation, Pharmacology (medical), virus diseases, 3. Good health, 030211 gastroenterology & hepatology, medicine.medical_specialty, Hepatitis C virus, 03 medical and health sciences, Internal medicine, medicine, Survival rate, business.industry, medicine.disease, digestive system diseases, Surgery, business
Abstract

Liver retransplantation is performed in HIV-infected patients, although its outcome is not well known. In an international cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients who had undergone liver transplant were retransplanted. The main indications for retransplantation were vascular complications (35%), primary graft nonfunction (22%), rejection (19%), and HCV recurrence (13%). Overall, 19 patients (51%) died after retransplantation. Survival at 1, 3, and 5 years was 56%, 51%, and 51%, respectively. Among patients with HCV coinfection, HCV RNA replication status at retransplantation was the only significant prognostic factor. Patients with undetectable versus detectable HCV RNA had a survival probability of 80% versus 39% at 1 year and 80% versus 30% at 3 and 5 years (p = 0.025). Recurrence of hepatitis C was the main cause of death in the latter. Patients with HBV coinfection had survival of 80% at 1, 3, and 5 years after retransplantation. HIV infection was adequately controlled with antiretroviral therapy. In conclusion, liver retransplantation is an acceptable option for HIV-infected patients with HBV or HCV coinfection but undetectable HCV RNA. Retransplantation in patients with HCV replication should be reassessed prospectively in the era of new direct antiviral agents. info:eu-repo/semantics/publishedVersion

Published
2016

37. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis

Author

Pericàs, J.M., primary, Messina, J.A., additional, Garcia-de-la-Mària, C., additional, Park, L., additional, Sharma-Kuinkel, B.K., additional, Marco, F., additional, Wray, D., additional, Kanafani, Z.A., additional, Carugati, M., additional, Durante-Mangoni, E., additional, Tattevin, P., additional, Chu, V.H., additional, Moreno, A., additional, Fowler, V.G., additional, Miró, J.M., additional, Athan, E., additional, Harris, O., additional, Korman, T.M., additional, Kotsanas, D., additional, Jones, P., additional, Reinbott, P., additional, Ryan, S., additional, Fortes, C.Q., additional, Garcia, P., additional, Jones, S.B., additional, Barsic, B., additional, Bukovski, S., additional, Selton-Suty, C., additional, Aissa, N., additional, Doco-Lecompte, T., additional, Delahaye, F., additional, Vandenesch, F., additional, Hoen, B., additional, Plesiat, P., additional, Giamarellou, H., additional, Giannitsioti, E., additional, Tarpatzi, E., additional, Iossa, D., additional, Orlando, S., additional, Ursi, M.P., additional, Pafundi, P.C., additional, D' Amico, F., additional, Bernardo, M., additional, Cuccurullo, S., additional, Dialetto, G., additional, Covino, F.E., additional, Manduca, S., additional, Della Corte, A., additional, De Feo, M., additional, Tripodi, M.F., additional, Baban, T., additional, Kanj, S.S., additional, Sfeir, J., additional, Yasmine, M., additional, Morris, A., additional, Murdoch, D.R., additional, Premru, M.M., additional, Lejko-Zupanc, T., additional, Almela, M., additional, Ambrosioni, J., additional, Azqueta, M., additional, Brunet, M., additional, Cervera, C., additional, De Lazzari, E., additional, Falces, C., additional, Fuster, D., additional, Garcia-Gonzalez, J., additional, Gatell, J.M., additional, Ortiz, J., additional, Ninot, S., additional, Paré, J.C., additional, Pericas, J.M., additional, Quintana, E., additional, Ramirez, J., additional, Sandoval, E., additional, Sitges, M., additional, Tolosana, J.M., additional, Vidal, B., additional, Vila, J., additional, Bouza, E., additional, Muñoz, P., additional, Rodríguez-Créixems, M., additional, Ramallo, V., additional, Bradley, S., additional, Steed, L., additional, Cantey, R., additional, Peterson, G., additional, Stancoven, A., additional, Woods, C., additional, Corey, G.R., additional, Reller, L.B., additional, Baloch, K., additional, Dixon, C.C., additional, Harding, T., additional, Jones-Richmond, M., additional, Pappas, P., additional, Park, L.P., additional, Redick, T., additional, Stafford, J., additional, Anstrom, K., additional, Bayer, A.S., additional, Cabell, C.H., additional, Karchmer, A.W., additional, Sexton, D.J., additional, Wang, A., additional, Chu, V., additional, Durack, D.T., additional, Eykyn, S., additional, Moreillon, P., additional, Olaison, L., additional, Raoult, D., additional, and Rubinstein, E., additional

Published
2017
Full Text
View/download PDF

39. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal beta-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis.

Author

Ambrosioni J., Covino F.E., Manduca S., Della Corte A., De Feo M., Tripodi M.F., Baban T., Kanj S.S., Sfeir J., Yasmine M., Morris A., Murdoch D.R., Premru M.M., Lejko-Zupanc T., Almela M., Azqueta M., Brunet M., Cervera C., De Lazzari E., Falces C., Fuster D., Garcia-Gonzalez J., Gatell J.M., Ortiz J., Ninot S., Pare J.C., Quintana E., Ramirez J., Sandoval E., Sitges M., Tolosana J.M., Vidal B., Vila J., Bouza E., Rodriguez-Creixems M., Ramallo V., Bradley S., Steed L., Cantey R., Peterson G., Stancoven A., Woods C., Reller L.B., Pericas J.M., Garcia-de-la-Maria C., Moreno A., Marco F., Sharma-Kuinkel B.K., Carugati M., Messina J.A., Park L., Wray D., Kanafani Z.A., Tattevin P., Munoz P., Baloch K., Dixon C.C., Harding T., Jones-Richmond M., Pappas P., Park L.P., Redick T., Stafford J., Anstrom K., Athan E., Chu V.H., Karchmer A.W., Wang A., Bayer A.S., Cabell C.H., Chu V., Corey G.R., Durack D.T., Eykyn S., Fowler V.G., Hoen B., Miro J.M., Sexton D.J., Moreillon P., Olaison L., Raoult D., Rubinstein E., Harris O., Korman T.M., Kotsanas D., Jones P., Reinbott P., Ryan S., Fortes C.Q., Garcia P., Jones S.B., Barsic B., Bukovski S., Selton-Suty C., Aissa N., Doco-Lecompte T., Delahaye F., Vandenesch F., Plesiat P., Giamarellou H., Giannitsioti E., Tarpatzi E., Durante-Mangoni E., Iossa D., Orlando S., Ursi M.P., Pafundi P.C., D' Amico F., Bernardo M., Cuccurullo S., Dialetto G., Ambrosioni J., Covino F.E., Manduca S., Della Corte A., De Feo M., Tripodi M.F., Baban T., Kanj S.S., Sfeir J., Yasmine M., Morris A., Murdoch D.R., Premru M.M., Lejko-Zupanc T., Almela M., Azqueta M., Brunet M., Cervera C., De Lazzari E., Falces C., Fuster D., Garcia-Gonzalez J., Gatell J.M., Ortiz J., Ninot S., Pare J.C., Quintana E., Ramirez J., Sandoval E., Sitges M., Tolosana J.M., Vidal B., Vila J., Bouza E., Rodriguez-Creixems M., Ramallo V., Bradley S., Steed L., Cantey R., Peterson G., Stancoven A., Woods C., Reller L.B., Pericas J.M., Garcia-de-la-Maria C., Moreno A., Marco F., Sharma-Kuinkel B.K., Carugati M., Messina J.A., Park L., Wray D., Kanafani Z.A., Tattevin P., Munoz P., Baloch K., Dixon C.C., Harding T., Jones-Richmond M., Pappas P., Park L.P., Redick T., Stafford J., Anstrom K., Athan E., Chu V.H., Karchmer A.W., Wang A., Bayer A.S., Cabell C.H., Chu V., Corey G.R., Durack D.T., Eykyn S., Fowler V.G., Hoen B., Miro J.M., Sexton D.J., Moreillon P., Olaison L., Raoult D., Rubinstein E., Harris O., Korman T.M., Kotsanas D., Jones P., Reinbott P., Ryan S., Fortes C.Q., Garcia P., Jones S.B., Barsic B., Bukovski S., Selton-Suty C., Aissa N., Doco-Lecompte T., Delahaye F., Vandenesch F., Plesiat P., Giamarellou H., Giannitsioti E., Tarpatzi E., Durante-Mangoni E., Iossa D., Orlando S., Ursi M.P., Pafundi P.C., D' Amico F., Bernardo M., Cuccurullo S., and Dialetto G.

Abstract

Objectives Left-sided methicillin-susceptible Staphylococcus aureus (MSSA) endocarditis treated with cloxacillin has a poorer prognosis when the vancomycin minimum inhibitory concentration (MIC) is >=1.5 mg/L. We aimed to validate this using the International Collaboration on Endocarditis cohort and to analyse whether specific genetic characteristics were associated with a high vancomycin MIC (>=1.5 mg/L) phenotype. Methods All patients with left-sided MSSA infective endocarditis treated with antistaphylococcal beta-lactam antibiotics between 2000 and 2006 with available isolates were included. Vancomycin MIC was determined by Etest as either high (>=1.5 mg/L) or low (<1.5 mg/L). Isolates underwent spa typing to infer clonal complexes and multiplex PCR for identifying virulence genes. Univariate analysis was performed to evaluate the association between in-hospital and 1-year mortality, and vancomycin MIC phenotype. Results Sixty-two cases met the inclusion criteria. Vancomycin MIC was low in 28 cases (45%) and high in 34 cases (55%). No significant differences in patient demographic data or characteristics of infection were observed between patients with infective endocarditis due to high and low vancomycin MIC isolates. Isolates with high and low vancomycin MIC had similar distributions of virulence genes and clonal lineages. In-hospital and 1-year mortality did not differ significantly between the two groups (32% (9/28) vs. 27% (9/34), p 0.780; and 43% (12/28) vs. 29% (10/34), p 0.298, for low and high vancomycin MIC respectively). Conclusions In this international cohort of patients with left-sided MSSA endocarditis treated with antistaphylococcal beta-lactams, vancomycin MIC phenotype was not associated with patient demographics, clinical outcome or virulence gene repertoire.Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases

Published
2017

40. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

Author

Antiretroviral Therapy Cohort Collaboration Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M, Chêne G, Costagliola D, Dabis F, D'Arminio Monforte A, de Wolf F, Ledergerber B, Mocroft A, Phillips A, Weller I, Sterne J, Abgrall S, Barin F, Bentata M, Billaud E, Boué F, Burty C, Cabié A, Cotte L, De Truchis P, Duval X, Duvivier C, Enel P, Fredouille Heripret L, Gasnault J, Gaud C, Gilquin J, Katlama C, Khuong MA, Lang JM, Lascaux AS, Launay O, Mahamat A, Mary Krause M, Matheron S, Meynard JL, Pavie J, Pialoux G, Pilorgé F, Poizot Martin I, Pradier C, Reynes J, Rouveix E, Simon A, Tattevin P, Tissot Dupont H, Viard JP, Viget N, Pariente Khayat A, Salomon V, Jacquemet N, Rivet A, Guiguet M, Kousignian I, Lanoy E, Lièvre L, Potard V, Selinger Leneman H, Bouvet E, Crickx B, Ecobichon JL, Leport C, Picard Dahan C, Yeni P, Tisne Dessus D, Weiss L, Salmon D, Sicard D, Auperin I, Roudière L, Fior R, Delfraissy JF, Goujard C, Jung C, Lesprit P, Desplanque N, Meyohas MC, Picard O, Cadranel J, Mayaud C, Bricaire F, Herson S, Clauvel JP, Decazes JM, Gerard L, Molina JM, Diemer M, Sellier P, Berthé H, Dupont C, Chandemerle C, Mortier E, Honoré P, Jeantils V, Tassi S, Mechali D, Taverne B, Gourdon F, Laurichesse H, Fresard A, Lucht F, Eglinger P, Faller JP, Bazin C, Verdon R, Boibieux A, Peyramond D, Livrozet JM, Touraine JL, Trepo C, Ravaux I, Delmont JP, Moreau J, Gastaut JA, Retornaz F, Soubeyrand J, Allegre T, Blanc PA, Galinier A, Ruiz JM, Lepeu G, Granet Brunello P, Esterni JP, Pelissier L, Cohen Valensi R, Nezri M, Chadapaud S, Laffeuillade A, May T, Rabaud C, Raffi F, Arvieux C, Michelet C, Borsa Lebas F, Caron F, Fraisse P, Rey D, Arlet Suau E, Cuzin L, Massip P, Thiercelin Legrand MF, Yasdanpanah Y, Pradinaud R, Sobesky M, Contant M, Montroni M, Scalise G, Braschi MC, Riva A, Tirelli U, Martellotta F, Pastore G, Ladisa N, Suter F, Arici C, Chiodo F, Colangeli V, Fiorini C, Carosi G, Cristini G, Torti C, Minardi C, Bertelli D, Quirino T, Manconi PE, Piano P, Cosco L, Scerbo A, Vecchiet J, D'Alessandro M, Santoro D, Pusterla L, Carnevale G, Lorenzotti S, Viganò P, Mena M, Ghinelli F, Sighinolfi L, Leoncini F, Mazzotta F, Pozzi M, Lo Caputo S, Grisorio B, Ferrara S, Grima P, Grima PF, Pagano G, Cassola G, Alessandrini A, Piscopo R, Toti M, Trezzi M, Soscia F, Tacconi L, Orani A, Perini P, Scasso A, Vincenti A, Chiodera F, Castelli P, Scalzini A, Palvarini L, Moroni M, Lazzarin A, Rizzardini G, Caggese L, Cicconi P, Galli A, Merli S, Pastecchia C, Moioli MC, Esposito R, Mussini C, Abrescia N, Chirianni A, Izzo CM, Piazza M, De Marco M, Viglietti R, Manzillo E, Colomba A, Abbadessa V, Prestileo T, Mancuso S, Ferrari C, Pizzaferri P, Filice G, Minoli L, Bruno R, Novati S, Baldelli F, Camanni G, Petrelli E, Cioppi A, Alberici F, Ruggieri A, Menichetti F, Martinelli C, De Stefano C, La Gala A, Ballardini G, Rizzo E, Magnani G, Ursitti MA, Arlotti M, Ortolani P, Cauda R, Dianzani F, Ippolito G, Antinori A, Antonucci G, Ciardi M, Narciso P, Petrosillo N, Vullo V, De Luca A, Zaccarelli M, Acinapura R, De Longis P, Trotta MP, Noto P, Lichtner M, Capobianchi MR, Carletti F, Girardi E, Pezzotti P, Rezza G, Mura MS, Mannazzu M, Caramello P, Di Perri G, Orofino GC, Sciandra M, Grossi PA, Basilico C, Poggio A, Bottari G, Raise E, Ebo F, Pellizzer G, Buonfrate D, Resta F, Loso K, Cozzi Lepri A, Battegay M, Bernasconi E, Böni J, Bucher H, Bürgisser P, Cattacin S, Cavassini M, Dubs R, Elzi L, Erb P, Fischer M, Flepp M, Fontana A, Francioli P, Gorgievski M, Günthard H, Hirsch H, Hirschel B, Hösli I, Kahlert C, Kaiser L, Karrer U, Kind C, Klimkait T, Martinetti G, Martinez B, Müller N, Nadal D, Opravil M, Paccaud F, Pantaleo G, Rickenbach M, Rudin C, Schmid P, Schultze D, Schüpbach J, Speck R, Taffé P, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S, Gras LA, van Sighem AI, Smit C, Bronsveld W, Hillebrand Haverkort ME, Prins JM, Branger J, Eeftinck Schattenkerk JK, Gisolf J, Godfried MH, Lange JM, Lettinga KD, van der Meer JT, Nellen FJ, van der Poll T, Ruys TA, Steingrover R, Vermeulen JN, Vrouenraets SM, van Vugt M, Wit FW, Kuijpers TW, Pajkrt D, Scherpbier HJ, van Eeden A, Brinkman K, van den Berk GE, Blok WL, Frissen PH, Roos JC, Schouten WE, Mulder JW, van Gorp EC, Wagenaar J, Veenstra J, Danner SA, Van Agtmael MA, Claessen FA, Perenboom RM, Rijkeboer A, van Vonderen MG, Richter C, van der Berg J, Vriesendorp R, Jeurissen FJ, Kauffmann RH, Pogány K, Bravenboer B, ten Napel CH, Kootstra GJ, Sprenger HG, van Assen S, van Leeuwen JT, Doedens R, Scholvinck EH, ten Kate RW, Soetekouw R, van Houte D, Polée MB, Kroon FP, van den Broek PJ, van Dissel JT, Schippers EF, Schreij G, van der Geest S, Lowe S, Verbon A, Koopmans PP, Van Crevel R, de Groot R, Keuter M, Post F, van der Ven AJ, Warris A, van der Ende ME, Gyssens IC, van der Feltz M, Nouwen JL, Rijnders BJ, de Vries TE, Driessen G, van der Flier M, Hartwig NG, Juttman JR, van Kasteren ME, Van de Heul C, Hoepelman IM, Schneider MM, Bonten MJ, Borleffs JC, Ellerbroek PM, Jaspers CA, Mudrikove T, Schurink CA, Gisolf EH, Geelen SP, Wolfs TF, Faber T, Tanis AA, Groeneveld PH, den Hollander JG, Duits AJ, Winkel K, Back NK, Bakker ME, Berkhout B, Jurriaans S, Zaaijer HL, Cuijpers T, Rietra PJ, Roozendaal KJ, Pauw W, van Zanten AP, Smits PH, von Blomberg BM, Savelkoul P, Pettersson A, Swanink CM, Franck PF, Lampe AS, Jansen CL, Hendriks R, Benne CA, Veenendaal D, Storm H, Weel J, van Zeijl JH, Kroes AC, Claas HC, Bruggeman CA, Goossens VJ, Galama JM, Melchers WJ, Poort YA, Doornum GJ, Niesters MG, Osterhaus AD, Schutten M, Buiting AG, Swaans CA, Boucher CA, Schuurman R, Boel E, Jansz AF, Veldkamp A, Beijnen JH, Huitema AD, Burger DM, Hugen PW, van Kan HJ, Losso M, Duran A, Vetter N, Karpov I, Vassilenko A, Mitsura VM, Suetnov O, Clumeck N, De Wit S, Poll B, Colebunders R, Kostov K, Begovac J, Machala L, Rozsypal H, Sedlacek D, Nielsen J, Lundgren J, Benfield T, Kirk O, Gerstoft J, Katzenstein T, Hansen AB, Skinhøj P, Pedersen C, Oestergaard L, Zilmer K, Ristola M, Girard PM, Vanhems P, Rockstroh J, Schmidt R, van Lunzen J, Degen O, Stellbrink HJ, Bogner J, Kosmidis J, Gargalianos P, Xylomenos G, Perdios J, Panos G, Filandras A, Karabatsaki E, Sambattakou H, Banhegyi D, Mulcahy F, Yust I, Turner D, Burke M, Pollack S, Hassoun G, Maayan S, Chiesi A, Mazeu I, Pristera R, Gabbuti A, Montesarchio E, Gargiulo M, Iacomi F, Vlassi C, Finazzi R, Galli M, Ridolfo A, Rozentale B, Aldins P, Chaplinskas S, Hemmer R, Staub T, Bruun J, Maeland A, Ormaasen V, Knysz B, Gasiorowski J, Horban A, Prokopowicz D, Wiercinska Drapalo A, Boron Kaczmarska A, Pynka M, Beniowski M, Mularska E, Trocha H, Antunes F, Valadas E, Mansinho K, Maltez F, Duiculescu D, Rakhmanova A, Vinogradova E, Buzunova S, Jevtovic D, Mokrás M, Staneková D, González Lahoz J, Soriano V, Martin Carbonero L, Labarga P, Clotet B, Jou A, Conejero J, Tural C, Gatell JM, Miró JM, Domingo P, Gutierrez M, Mateo G, Sambeat MA, Karlsson A, Persson PO, Flamholc L, Boffi E, Kravchenko E, Chentsova N, Barton S, Johnson AM, Mercey D, Johnson MA, Murphy M, Weber J, Scullard G, Fisher M, Brettle R, Gatell J, Gazzard B, Friis Møller N, Bannister W, Ellefson M, Borch A, Podlekareva D, Holkmann Olsen C, Kjaer J, Peters L, Reekie J, Raffanti S, Dieterch D, Becker S, Scarsella A, Fusco G, Most B, Balu R, Rana R, Beckerman R, Ising T, Fusco J, Irek R, Johnson B, Hirani A, DeJesus E, Pierone G, Lackey P, Irek C, Johnson A, Burdick J, Leon S, Arch J, Helm EB, Carlebach A, Müller A, Haberl A, Nisius G, Lennemann T, Stephan C, Bickel M, Mösch M, Gute P, Locher L, Lutz T, Klauke S, Knecht G, Khaykin P, Doerr HW, Stürmer M, Babacan E, von Hentig N, Beylot J, Dupon M, Longy Boursier M, Pellegrin JL, Ragnaud JM, Salamon R, Thiébaut R, Lewden C, Lawson Ayayi S, Mercié P, Moreau JF, Morlat P, Bernard N, Lacoste D, Malvy D, Neau D, Blaizeau MJ, Decoin M, Delveaux S, Hannapier C, Labarrère S, Lavignolle Aurillac V, Uwamaliya Nziyumvira B, Palmer G, Touchard D, Balestre E, Alioum A, Jacqmin Gadda H, Bonarek M, Coadou B, Gellie P, Nouts C, Bocquentin F, Dutronc H, Lafarie S, Aslan A, Pistonne T, Thibaut P, Vatan R, Chambon D, De La Taille C, Cazorla C, Ocho A, Viallard JF, Caubet O, Cipriano C, Lazaro E, Couzigou P, Castera L, Fleury H, Lafon ME, Masquelier B, Pellegrin I, Breilh D, Blanco P, Loste P, Caunègre L, Bonnal F, Farbos S, Ferrand M, Ceccaldi J, Tchamgoué S, De Witte S, Buy E, Alexander C, Barrios R, Braitstein P, Brumme Z, Chan K, Cote H, Gataric N, Geller J, Guillemi S, Harrigan PR, Harris M, Joy R, Levy A, Montaner J, Montessori V, Palepu A, Phillips E, Phillips P, Press N, Tyndall M, Wood E, Yip B, Bhagani S, Breen R, Byrne P, Carroll A, Cuthbertson Z, Dunleavy A, Geretti AM, Heelan B, Johnson M, Kinloch de Loes S, Lipman M, Madge S, Marshall N, Nair D, Nebbia G, Prinz B, Shah S, Swader L, Tyrer M, Youle M, Chaloner C, Grabowska H, Holloway J, Puradiredja J, Ransom D, Tsintas R, Bansi L, Fox Z, Harris E, Hill T, Lampe F, Lodwick R, Smith C, Amoah E, Booth C, Clewley G, Garcia Diaz A, Gregory B, Janossy G, Labbett W, Thomas M, Read R, Krentz H, Beckthold B, Schmeisser N, Alquézar A, Esteve A, Podzamczer D, Murillas J, Romero A, Agustí C, Agüero F, Ferrer E, Riera M, Segura F, Navarro G, Force L, Vilaró J, Masabeu A, García I, Guadarrama M, Montoliu A, Ortega N, Lazzari E, Puchol E, Sanchez M, Blanco JL, Garcia Alcaide F, Martinez E, Mallolas J, López Dieguez M, García Goez JF, Sirera G, Romeu J, Negredo E, Miranda C, Capitan MC, Olmo M, Barragan P, Saumoy M, Bolao F, Cabellos C, Peña C, Sala M, Cervantes M, Jose Amengual M, Navarro M, Penelo E, Barrufet P, Raper JL, Mugavero MJ, Willig JH, Schumacher J, Chang PW, Westfall AO, Cloud G, Lin HY, Acosta EP, Colette Kempf M, Allison JJ, Pisu M., NAPPA, SALVATORE, Mocroft, A, Mancuso, S, Antiretroviral Therapy Cohort Collaboration Mocroft, A, Sterne, Ja, Egger, M, May, M, Grabar, S, Furrer, H, Sabin, C, Fatkenheuer, G, Justice, A, Reiss, P, d'Arminio Monforte, A, Gill, J, Hogg, R, Bonnet, F, Kitahata, M, Staszewski, S, Casabona, J, Harris, R, Saag, M, Chêne, G, Costagliola, D, Dabis, F, D'Arminio Monforte, A, de Wolf, F, Ledergerber, B, Phillips, A, Weller, I, Sterne, J, Abgrall, S, Barin, F, Bentata, M, Billaud, E, Boué, F, Burty, C, Cabié, A, Cotte, L, De Truchis, P, Duval, X, Duvivier, C, Enel, P, Fredouille Heripret, L, Gasnault, J, Gaud, C, Gilquin, J, Katlama, C, Khuong, Ma, Lang, Jm, Lascaux, A, Launay, O, Mahamat, A, Mary Krause, M, Matheron, S, Meynard, Jl, Pavie, J, Pialoux, G, Pilorgé, F, Poizot Martin, I, Pradier, C, Reynes, J, Rouveix, E, Simon, A, Tattevin, P, Tissot Dupont, H, Viard, Jp, Viget, N, Pariente Khayat, A, Salomon, V, Jacquemet, N, Rivet, A, Guiguet, M, Kousignian, I, Lanoy, E, Lièvre, L, Potard, V, Selinger Leneman, H, Bouvet, E, Crickx, B, Ecobichon, Jl, Leport, C, Picard Dahan, C, Yeni, P, Tisne Dessus, D, Weiss, L, Salmon, D, Sicard, D, Auperin, I, Roudière, L, Fior, R, Delfraissy, Jf, Goujard, C, Jung, C, Lesprit, P, Desplanque, N, Meyohas, Mc, Picard, O, Cadranel, J, Mayaud, C, Bricaire, F, Herson, S, Clauvel, Jp, Decazes, Jm, Gerard, L, Molina, Jm, Diemer, M, Sellier, P, Berthé, H, Dupont, C, Chandemerle, C, Mortier, E, Honoré, P, Jeantils, V, Tassi, S, Mechali, D, Taverne, B, Gourdon, F, Laurichesse, H, Fresard, A, Lucht, F, Eglinger, P, Faller, Jp, Bazin, C, Verdon, R, Boibieux, A, Peyramond, D, Livrozet, Jm, Touraine, Jl, Trepo, C, Ravaux, I, Delmont, Jp, Moreau, J, Gastaut, Ja, Retornaz, F, Soubeyrand, J, Allegre, T, Blanc, Pa, Galinier, A, Ruiz, Jm, Lepeu, G, Granet Brunello, P, Esterni, Jp, Pelissier, L, Cohen Valensi, R, Nezri, M, Chadapaud, S, Laffeuillade, A, May, T, Rabaud, C, Raffi, F, Arvieux, C, Michelet, C, Borsa Lebas, F, Caron, F, Fraisse, P, Rey, D, Arlet Suau, E, Cuzin, L, Massip, P, Thiercelin Legrand, Mf, Yasdanpanah, Y, Pradinaud, R, Sobesky, M, Contant, M, Montroni, M, Scalise, G, Braschi, Mc, Riva, A, Tirelli, U, Martellotta, F, Pastore, G, Ladisa, N, Suter, F, Arici, C, Chiodo, F, Colangeli, V, Fiorini, C, Carosi, G, Cristini, G, Torti, C, Minardi, C, Bertelli, D, Quirino, T, Manconi, Pe, Piano, P, Cosco, L, Scerbo, A, Vecchiet, J, D'Alessandro, M, Santoro, D, Pusterla, L, Carnevale, G, Lorenzotti, S, Viganò, P, Mena, M, Ghinelli, F, Sighinolfi, L, Leoncini, F, Mazzotta, F, Pozzi, M, Lo Caputo, S, Grisorio, B, Ferrara, S, Grima, P, Grima, Pf, Pagano, G, Cassola, G, Alessandrini, A, Piscopo, R, Toti, M, Trezzi, M, Soscia, F, Tacconi, L, Orani, A, Perini, P, Scasso, A, Vincenti, A, Chiodera, F, Castelli, P, Scalzini, A, Palvarini, L, Moroni, M, Lazzarin, A, Rizzardini, G, Caggese, L, Cicconi, P, Galli, A, Merli, S, Pastecchia, C, Moioli, Mc, Esposito, R, Mussini, C, Abrescia, N, Chirianni, A, Izzo, Cm, Piazza, M, De Marco, M, Viglietti, R, Manzillo, E, Nappa, Salvatore, Colomba, A, Abbadessa, V, Prestileo, T, Ferrari, C, Pizzaferri, P, Filice, G, Minoli, L, Bruno, R, Novati, S, Baldelli, F, Camanni, G, Petrelli, E, Cioppi, A, Alberici, F, Ruggieri, A, Menichetti, F, Martinelli, C, De Stefano, C, La Gala, A, Ballardini, G, Rizzo, E, Magnani, G, Ursitti, Ma, Arlotti, M, Ortolani, P, Cauda, R, Dianzani, F, Ippolito, G, Antinori, A, Antonucci, G, Ciardi, M, Narciso, P, Petrosillo, N, Vullo, V, De Luca, A, Zaccarelli, M, Acinapura, R, De Longis, P, Trotta, Mp, Noto, P, Lichtner, M, Capobianchi, Mr, Carletti, F, Girardi, E, Pezzotti, P, Rezza, G, Mura, M, Mannazzu, M, Caramello, P, Di Perri, G, Orofino, Gc, Sciandra, M, Grossi, Pa, Basilico, C, Poggio, A, Bottari, G, Raise, E, Ebo, F, Pellizzer, G, Buonfrate, D, Resta, F, Loso, K, Cozzi Lepri, A, Battegay, M, Bernasconi, E, Böni, J, Bucher, H, Bürgisser, P, Cattacin, S, Cavassini, M, Dubs, R, Elzi, L, Erb, P, Fischer, M, Flepp, M, Fontana, A, Francioli, P, Gorgievski, M, Günthard, H, Hirsch, H, Hirschel, B, Hösli, I, Kahlert, C, Kaiser, L, Karrer, U, Kind, C, Klimkait, T, Martinetti, G, Martinez, B, Müller, N, Nadal, D, Opravil, M, Paccaud, F, Pantaleo, G, Rickenbach, M, Rudin, C, Schmid, P, Schultze, D, Schüpbach, J, Speck, R, Taffé, P, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, Gras, La, van Sighem, Ai, Smit, C, Bronsveld, W, Hillebrand Haverkort, Me, Prins, Jm, Branger, J, Eeftinck Schattenkerk, Jk, Gisolf, J, Godfried, Mh, Lange, Jm, Lettinga, Kd, van der Meer, Jt, Nellen, Fj, van der Poll, T, Ruys, Ta, Steingrover, R, Vermeulen, Jn, Vrouenraets, Sm, van Vugt, M, Wit, Fw, Kuijpers, Tw, Pajkrt, D, Scherpbier, Hj, van Eeden, A, Brinkman, K, van den Berk, Ge, Blok, Wl, Frissen, Ph, Roos, Jc, Schouten, We, Mulder, Jw, van Gorp, Ec, Wagenaar, J, Veenstra, J, Danner, Sa, Van Agtmael, Ma, Claessen, Fa, Perenboom, Rm, Rijkeboer, A, van Vonderen, Mg, Richter, C, van der Berg, J, Vriesendorp, R, Jeurissen, Fj, Kauffmann, Rh, Pogány, K, Bravenboer, B, ten Napel, Ch, Kootstra, Gj, Sprenger, Hg, van Assen, S, van Leeuwen, Jt, Doedens, R, Scholvinck, Eh, ten Kate, Rw, Soetekouw, R, van Houte, D, Polée, Mb, Kroon, Fp, van den Broek, Pj, van Dissel, Jt, Schippers, Ef, Schreij, G, van der Geest, S, Lowe, S, Verbon, A, Koopmans, Pp, Van Crevel, R, de Groot, R, Keuter, M, Post, F, van der Ven, Aj, Warris, A, van der Ende, Me, Gyssens, Ic, van der Feltz, M, Nouwen, Jl, Rijnders, Bj, de Vries, Te, Driessen, G, van der Flier, M, Hartwig, Ng, Juttman, Jr, van Kasteren, Me, Van de Heul, C, Hoepelman, Im, Schneider, Mm, Bonten, Mj, Borleffs, Jc, Ellerbroek, Pm, Jaspers, Ca, Mudrikove, T, Schurink, Ca, Gisolf, Eh, Geelen, Sp, Wolfs, Tf, Faber, T, Tanis, Aa, Groeneveld, Ph, den Hollander, Jg, Duits, Aj, Winkel, K, Back, Nk, Bakker, Me, Berkhout, B, Jurriaans, S, Zaaijer, Hl, Cuijpers, T, Rietra, Pj, Roozendaal, Kj, Pauw, W, van Zanten, Ap, Smits, Ph, von Blomberg, Bm, Savelkoul, P, Pettersson, A, Swanink, Cm, Franck, Pf, Lampe, A, Jansen, Cl, Hendriks, R, Benne, Ca, Veenendaal, D, Storm, H, Weel, J, van Zeijl, Jh, Kroes, Ac, Claas, Hc, Bruggeman, Ca, Goossens, Vj, Galama, Jm, Melchers, Wj, Poort, Ya, Doornum, Gj, Niesters, Mg, Osterhaus, Ad, Schutten, M, Buiting, Ag, Swaans, Ca, Boucher, Ca, Schuurman, R, Boel, E, Jansz, Af, Veldkamp, A, Beijnen, Jh, Huitema, Ad, Burger, Dm, Hugen, Pw, van Kan, Hj, Losso, M, Duran, A, Vetter, N, Karpov, I, Vassilenko, A, Mitsura, Vm, Suetnov, O, Clumeck, N, De Wit, S, Poll, B, Colebunders, R, Kostov, K, Begovac, J, Machala, L, Rozsypal, H, Sedlacek, D, Nielsen, J, Lundgren, J, Benfield, T, Kirk, O, Gerstoft, J, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Oestergaard, L, Zilmer, K, Ristola, M, Girard, Pm, Vanhems, P, Rockstroh, J, Schmidt, R, van Lunzen, J, Degen, O, Stellbrink, Hj, Bogner, J, Kosmidis, J, Gargalianos, P, Xylomenos, G, Perdios, J, Panos, G, Filandras, A, Karabatsaki, E, Sambattakou, H, Banhegyi, D, Mulcahy, F, Yust, I, Turner, D, Burke, M, Pollack, S, Hassoun, G, Maayan, S, Chiesi, A, Mazeu, I, Pristera, R, Gabbuti, A, Montesarchio, E, Gargiulo, M, Iacomi, F, Vlassi, C, Finazzi, R, Galli, M, Ridolfo, A, Rozentale, B, Aldins, P, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Prokopowicz, D, Wiercinska Drapalo, A, Boron Kaczmarska, A, Pynka, M, Beniowski, M, Mularska, E, Trocha, H, Antunes, F, Valadas, E, Mansinho, K, Maltez, F, Duiculescu, D, Rakhmanova, A, Vinogradova, E, Buzunova, S, Jevtovic, D, Mokrás, M, Staneková, D, González Lahoz, J, Soriano, V, Martin Carbonero, L, Labarga, P, Clotet, B, Jou, A, Conejero, J, Tural, C, Gatell, Jm, Miró, Jm, Domingo, P, Gutierrez, M, Mateo, G, Sambeat, Ma, Karlsson, A, Persson, Po, Flamholc, L, Boffi, E, Kravchenko, E, Chentsova, N, Barton, S, Johnson, Am, Mercey, D, Johnson, Ma, Murphy, M, Weber, J, Scullard, G, Fisher, M, Brettle, R, Gatell, J, Gazzard, B, Friis Møller, N, Bannister, W, Ellefson, M, Borch, A, Podlekareva, D, Holkmann Olsen, C, Kjaer, J, Peters, L, Reekie, J, Raffanti, S, Dieterch, D, Becker, S, Scarsella, A, Fusco, G, Most, B, Balu, R, Rana, R, Beckerman, R, Ising, T, Fusco, J, Irek, R, Johnson, B, Hirani, A, Dejesus, E, Pierone, G, Lackey, P, Irek, C, Johnson, A, Burdick, J, Leon, S, Arch, J, Helm, Eb, Carlebach, A, Müller, A, Haberl, A, Nisius, G, Lennemann, T, Stephan, C, Bickel, M, Mösch, M, Gute, P, Locher, L, Lutz, T, Klauke, S, Knecht, G, Khaykin, P, Doerr, Hw, Stürmer, M, Babacan, E, von Hentig, N, Beylot, J, Dupon, M, Longy Boursier, M, Pellegrin, Jl, Ragnaud, Jm, Salamon, R, Thiébaut, R, Lewden, C, Lawson Ayayi, S, Mercié, P, Moreau, Jf, Morlat, P, Bernard, N, Lacoste, D, Malvy, D, Neau, D, Blaizeau, Mj, Decoin, M, Delveaux, S, Hannapier, C, Labarrère, S, Lavignolle Aurillac, V, Uwamaliya Nziyumvira, B, Palmer, G, Touchard, D, Balestre, E, Alioum, A, Jacqmin Gadda, H, Bonarek, M, Coadou, B, Gellie, P, Nouts, C, Bocquentin, F, Dutronc, H, Lafarie, S, Aslan, A, Pistonne, T, Thibaut, P, Vatan, R, Chambon, D, De La Taille, C, Cazorla, C, Ocho, A, Viallard, Jf, Caubet, O, Cipriano, C, Lazaro, E, Couzigou, P, Castera, L, Fleury, H, Lafon, Me, Masquelier, B, Pellegrin, I, Breilh, D, Blanco, P, Loste, P, Caunègre, L, Bonnal, F, Farbos, S, Ferrand, M, Ceccaldi, J, Tchamgoué, S, De Witte, S, Buy, E, Alexander, C, Barrios, R, Braitstein, P, Brumme, Z, Chan, K, Cote, H, Gataric, N, Geller, J, Guillemi, S, Harrigan, Pr, Harris, M, Joy, R, Levy, A, Montaner, J, Montessori, V, Palepu, A, Phillips, E, Phillips, P, Press, N, Tyndall, M, Wood, E, Yip, B, Bhagani, S, Breen, R, Byrne, P, Carroll, A, Cuthbertson, Z, Dunleavy, A, Geretti, Am, Heelan, B, Johnson, M, Kinloch de Loes, S, Lipman, M, Madge, S, Marshall, N, Nair, D, Nebbia, G, Prinz, B, Shah, S, Swader, L, Tyrer, M, Youle, M, Chaloner, C, Grabowska, H, Holloway, J, Puradiredja, J, Ransom, D, Tsintas, R, Bansi, L, Fox, Z, Harris, E, Hill, T, Lampe, F, Lodwick, R, Smith, C, Amoah, E, Booth, C, Clewley, G, Garcia Diaz, A, Gregory, B, Janossy, G, Labbett, W, Thomas, M, Read, R, Krentz, H, Beckthold, B, Schmeisser, N, Alquézar, A, Esteve, A, Podzamczer, D, Murillas, J, Romero, A, Agustí, C, Agüero, F, Ferrer, E, Riera, M, Segura, F, Navarro, G, Force, L, Vilaró, J, Masabeu, A, García, I, Guadarrama, M, Montoliu, A, Ortega, N, Lazzari, E, Puchol, E, Sanchez, M, Blanco, Jl, Garcia Alcaide, F, Martinez, E, Mallolas, J, López Dieguez, M, García Goez, Jf, Sirera, G, Romeu, J, Negredo, E, Miranda, C, Capitan, Mc, Olmo, M, Barragan, P, Saumoy, M, Bolao, F, Cabellos, C, Peña, C, Sala, M, Cervantes, M, Jose Amengual, M, Navarro, M, Penelo, E, Barrufet, P, Raper, Jl, Mugavero, Mj, Willig, Jh, Schumacher, J, Chang, Pw, Westfall, Ao, Cloud, G, Lin, Hy, Acosta, Ep, Colette Kempf, M, Allison, Jj, Pisu, M., Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Infectious diseases, Other departments, General Internal Medicine, Graduate School, Global Health, Paediatric Infectious Diseases / Rheumatology / Immunology, and Medical Microbiology and Infection Prevention

Subjects
Male, Infectious diseases and international health [NCEBP 13], Lymphoma, 030312 virology, Esophageal candidiasis, Cohort Studies, 0302 clinical medicine, Interquartile range, 030212 general & internal medicine, AIDS-Related, Lymphoma, AIDS-Related, 0303 health sciences, Mortality rate, Progressive multifocal leukoencephalopathy, Hazard ratio, Prognosis, 3. Good health, Pathogenesis and modulation of inflammation [N4i 1], Infectious Diseases, Combination, Drug Therapy, Combination, Female, Infection and autoimmunity [NCMLS 1], Human, Microbiology (medical), Adult, medicine.medical_specialty, Prognosi, Anti-HIV Agents, antiretroviral therapy, Infectious Disease, Article, AIDS-Related Opportunistic Infection, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Drug Therapy, Internal medicine, medicine, Humans, AIDS-defining event, Proportional Hazards Models, AIDS-Related Opportunistic Infections/diagnosis/ mortality, Acquired Immunodeficiency Syndrome/complications/diagnosis/drug, therapy/ mortality, Anti-HIV Agents/ therapeutic use, AIDS-Related/diagnosis/mortality, Acquired Immunodeficiency Syndrome, AIDS-Related Opportunistic Infections, business.industry, Proportional hazards model, Poverty-related infectious diseases [N4i 3], Anti-HIV Agent, medicine.disease, mortality, Confidence interval, Immunology, Proportional Hazards Model, Cohort Studie, business
Abstract

Contains fulltext : 80963.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretroviral therapy, and CD4+ cell count and HIV RNA load at initiation of combination antiretroviral therapy. ADEs that occurred in

Published
2009
Full Text
View/download PDF

41. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition

Author

Benito N, Miró JM, de Lazzari E, Cabell CH, del Río A, Altclas J, Commerford P, Delahaye F, Dragulescu S, Giamarellou H, Habib G, Kamarulzaman A, Kumar AS, Nacinovich FM, Suter F, Tribouilloy C, Venugopal K, Moreno A, Fowler VG Jr, among ICE PCS Investigators, UTILI, Riccardo, Humbert, Murielle, Benito, N, Miró, Jm, de Lazzari, E, Cabell, Ch, del Río, A, Altclas, J, Commerford, P, Delahaye, F, Dragulescu, S, Giamarellou, H, Habib, G, Kamarulzaman, A, Kumar, A, Nacinovich, Fm, Suter, F, Tribouilloy, C, Venugopal, K, Moreno, A, Fowler VG, Jr, among ICE PCS, Investigator, and Utili, Riccardo

Subjects
Adult, Male, medicine.medical_specialty, Article, Ambulatory care, Renal Dialysis, Risk Factors, Health care, Epidemiology, Internal Medicine, medicine, Ambulatory Care, Endocarditis, Humans, Prospective Studies, Intensive care medicine, Aged, Ultrasonography, Native Valve Endocarditis, Cross Infection, business.industry, Public health, nosocomial, General Medicine, Endocarditis, Bacterial, Middle Aged, medicine.disease, Cardiac surgery, Community-Acquired Infections, Treatment Outcome, Endocarditis, nosocomial, S.aureus, S.aureus, Bacteremia, endocarditis, health-care associated infections, Female, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, business
Abstract

BACKGROUND: The clinical profile and outcome of nosocomial and non-nosocomial health care-associated native valve endocarditis are not well defined. OBJECTIVE: To compare the characteristics and outcomes of community-associated and nosocomial and non-nosocomial health care-associated native valve endocarditis. DESIGN: Prospective cohort study. SETTING: 61 hospitals in 28 countries. PATIENTS: Patients with definite native valve endocarditis and no history of injection drug use who were enrolled in the ICE-PCS (International Collaboration on Endocarditis Prospective Cohort Study) from June 2000 to August 2005. MEASUREMENTS: Clinical and echocardiographic findings, microbiology, complications, and mortality. RESULTS: Health care-associated native valve endocarditis was present in 557 (34%) of 1622 patients (303 with nosocomial infection [54%] and 254 with non-nosocomial infection [46%]). Staphylococcus aureus was the most common cause of health care-associated infection (nosocomial, 47%; non-nosocomial, 42%; P = 0.30); a high proportion of patients had methicillin-resistant S. aureus (nosocomial, 57%; non-nosocomial, 41%; P = 0.014). Fewer patients with health care-associated native valve endocarditis had cardiac surgery (41% vs. 51% of community-associated cases; P < 0.001), but more of the former patients died (25% vs. 13%; P < 0.001). Multivariable analysis confirmed greater mortality associated with health care-associated native valve endocarditis (incidence risk ratio, 1.28 [95% CI, 1.02 to 1.59]). LIMITATIONS: Patients were treated at hospitals with cardiac surgery programs. The results may not be generalizable to patients receiving care in other types of facilities or to those with prosthetic valves or past injection drug use. CONCLUSION: More than one third of cases of native valve endocarditis in non-injection drug users involve contact with health care, and non-nosocomial infection is common, especially in the United States. Clinicians should recognize that outpatients with extensive out-of-hospital health care contacts who develop endocarditis have clinical characteristics and outcomes similar to those of patients with nosocomial infection. PRIMARY FUNDING SOURCE: None.

Published
2009

43. I TEATRI PERDUTI DI PADOVA

Author

CATTIODORO, Silvia, AUTIZI, MB, LITARDI, A, MACCHIETTO, M, BOBISUT, D, CONTE, R, SCARPA, F, POSSAMAI VITA, A, BEDIN, N, BOSCARDIN, L, SCARSO, M, DE LAZZARI, E, BRUNETTA MENATO, M, CAMPAGNARO, L, PATRONE, P, GASTALDI, E, AVESANI, R, MATINO, U, GIORATO, S, ZANON, T, REBESCHINI, C, BERGAMIN, N, VEDOVATO, M, MONTI, G, TOSATO, R, MURATORI, G, GUMIERO SALOMONI, L, BELLINATI, A., MIRELLA CISOTTO NALON, CATTIODORO, S, AUTIZI, MB, LITARDI, A, MACCHIETTO, M, BOBISUT, D, CONTE, R, SCARPA, F, POSSAMAI VITA, A, BEDIN, N, BOSCARDIN, L, SCARSO, M, DE LAZZARI, E, BRUNETTA MENATO, M, CAMPAGNARO, L, PATRONE, P, GASTALDI, E, AVESANI, R, MATINO, U, GIORATO, S, ZANON, T, REBESCHINI, C, BERGAMIN, N, VEDOVATO, M, MONTI, G, TOSATO, R, MURATORI, G, GUMIERO SALOMONI, L, and BELLINATI, A

Subjects
TEATRO, PADOVA, SPETTACOLO
Published
2004

45. Long‐term outcomes of switching to fixed‐dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3‐year results of the BICOMBO study

Author

Martínez, E, Arranz, Ja, Podzamczer, D, Lonca, M, Sanz, J, Barragán, P, Knobel, H, Ribera, E, Gutierrez, F, Valero, S, Clotet, B, Dalmau, D, Segura, F, Arribas, Jr, Barrufet, P, Santos, I, Payeras, A, Lazzari, E, Pich, J, and Gatell, J

Subjects
Abacavir -- Dosage and administration -- Patient outcomes, Antiviral agents -- Dosage and administration -- Patient outcomes, Anti-HIV agents -- Dosage and administration -- Patient outcomes, Drug therapy, Combination -- Patient outcomes, HIV infection -- Drug therapy -- Patient outcomes, Health
Abstract

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, Background Once‐daily fixed‐dose combinations ABC/3TC and TDF/FTC are the preferred backbones in Europe [1]. Long‐term (>2 years) efficacy and safety of these compounds in simplification strategies are unknown. Methods 333 [...]

Published
2010
Full Text
View/download PDF

46. TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality

Author

Efsen, A. M. W., Panteleev, A. M., Grint, D., Podlekareva, D. N., Vassilenko, A., Rakhmanova, A., Zeltina, I., Losso, M. H., Miller, R. F., Girardi, E., Cayla, J., Post, F. A., Miro, J. M., Bruyand, M., Furrer, H., Obel, N., Lundgren, J. D., Mocroft, A., Kirk, O., Toibaro, J. J., Warley, E., Tamayo, N., Cristina Ortiz, M., Scapelatto, P., Bottaro, E., Murano, F., Miachans, M., Contarelli, J., Massera, L., Corral, J., Hualde, M., Miglioranza, C., Corti, M., Metta, H., Casiro, A., Cuini, R., Laplume, H., David, D., Marson, C., Lupo, S., Trape, L., Garcia Messina, O., Gear, O., Bruguera, J. M., Karpov, I., Skrahina, E., Skrahin, A., Zhavoronok, S., Mitsura, V., Ruzanov, D., Bondarenko, V., Suetnov, O., Paduto, D., Gerstoft, J., Kronborg, G., Pedersen, C., Larsen, C. S., Pedersen, G., Laursen, A. L., Nielsen, L., Jensen, J., Dabis, F., Chene, G., Lawson-Ayayi, S., Thiebaut, R., Wittkop, L., Morlat, P., Bonnet, F., Bernard, N., Hessamfar, M., Lacoste, D., Vandenhende, M. A., Dupon, M., Dauchy, F. A., Dutronc, H., Longy-Boursier, M., Mercie, P., Duffau, P., Roger Schmeltz, J., Malvy, D., Pistone, T., Receveur, M. C., Neau, D., Cazanave, C., Ochoa, A., Vareil, M. O., Pellegrin, J. L., Viallard, J. F., Greib, C., Lazaro, E., Fleury, H., Lafon, M. E., Reigadas, S., Trimoulet, P., Breilh, D., Molimard, M., Bouchet, S., Titier, K., Moreau, J. F., Pellegrin, I., Haramburu, F., Arcachon, G., Dupont, A., Gerard, Y., Caunegre, L., Andre, K., Bonnal, F., Farbos, S., Gemain, M. C., Ceccaldi, J., Tchamgoue, S., De Witte, S., Courtault, K., Monlun, E., Gaborieau, V., Lataste, P., Meraud, J. P., Chossat, I., Carvalho, A. C., Basche, R., Hamad, I. E., Ricci, B. A., Maggiolo, F., Ravasio, V., Mussini, C., Prati, F., Castelletti, S., Ammassari, A., Antinori, A., Bellagamba, R., Busi Rizzi, E., Cicalini, S., Corpolongo, A., Capaldo, A., Di Caro, A., Goletti, D., Grisetti, S., Gualano, G., Lauria, F. N., Parracino, L., Palmieri, F., Petrosillo, N., Pinetti, C., Sampaolesi, A., Moroni, M., Angarano, G., Armignacco, O., d'Arminio Monforte, A., Castelli, F., Cauda, R., Di Perri, G., Galli, M., Iardino, R., Guzzinati, Ippolito, Lazzarin, A., Perno, C. F., von Schloesser, F., Viale, P., Castagna, A., Ceccherini-Silberstein, F., Cozzi-Lepri, A., Lo Caputo, S., Puoti, M., Andreoni, M., Balotta, C., Bonfanti, P., Bonora, S., Borderi, M., Capobianchi, M. R., Cingolani, A., Cinque, P., De Luca, A., Di Biagio, A., Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Marchetti, G., Marcotullio, S., Monno, L., Quiros Roldan, E., Rusconi, S., Cicconi, P., Fanti, I., Formenti, T., Galli, L., Lorenzini, P., Giacometti, A., Costantini, A., Carrisa, C., Suardi, C., Vanino, E., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Cassola, G., Viscoli, G., Alessandrini, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Puzzolante, C., Abrescia, N., Chirianni, A., Guida, M. G., Gargiulo, M., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Vullo, V., D'Avino, A., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Tebano, G., Cattelan, A., Mura, M. S., Caramello, P., Orofino, G. C., Sciandra, M., Pellizzer, G., Manfrin, V., Riekstina, V., Aldins, P., Duiculescu, D., Malashenkov, E., Kozlov, A., Buzunova, S., Garcia-Goez, J. F., Moreno Camacho, A., Martinez, J. A., Gonzalez, J., Garcia-Alcaide, F., de Lazzari, E., Gatell, J. M., Sanchez, P., Lopezcolomes, J. L., Martinez-Lacasa, X., Falco, V., Imaz, A., Ocana, I., Vidal, R., Sambeat, M. A., Moreno-Martinez, A., Orcau, A., Weber, R., Battegay, M., Hirschel, B., Cavassini, M., Bernasconi, E., Schmid, P., Rickenbach, M., Campbell, L., Arenas-Pinto, A., Chentsova, N., Kjaer, J., Efsen, Anne Marie W., Panteleev, Alexander M., Grint, Daniel, Podlekareva, Daria N., Vassilenko, Anna, Rakhmanova, Aza, Zeltina, Indra, Losso, Marcelo H., Miller, Robert F., Girardi, Enrico, Caylã¡, Joan, Post, Frank A., Miro, Jose M., Bruyand, Mathia, Furrer, Hansjakob, Obel, Niel, Lundgren, Jens D., Mocroft, Amanda, Kirk, Ole, Hiv/tb Study, Group, Castagna, Antonella, Efsen, A, Panteleev, A, Grint, D, Podlekareva, D, Vassilenko, A, Rakhmanova, A, Zeltina, I, Losso, M, Miller, R, Girardi, E, Caylá, J, Post, F, Miro, J, Bruyand, M, Furrer, H, Obel, N, Lundgren, J, Mocroft, A, Kirk, O, and Gori, A

Subjects
Genetics and Molecular Biology (all), Male, Pediatrics, Meningeal, Immunology and Microbiology (all), lcsh:Medicine, HIV Infections, Kaplan-Meier Estimate, Rate ratio, Biochemistry, Risk Factors, Adult, Argentina, CD4 Lymphocyte Count, Europe, Female, HIV, Humans, Treatment Outcome, Tuberculosis, Meningeal, Biochemistry, Genetics and Molecular Biology (all), HIV Infection, Mortality rate, General Medicine, symbols, Meningitis, Human, Research Article, medicine.medical_specialty, Tuberculosis, Settore MED/17 - Malattie Infettive, Article Subject, General Biochemistry, Genetics and Molecular Biology, Tuberculous meningitis, NO, symbols.namesake, Pharmacotherapy, medicine, Poisson regression, General Immunology and Microbiology, business.industry, Public health, Risk Factor, lcsh:R, medicine.disease, Immunology, business
Abstract

Objectives.The study aimed at describing characteristics and outcome of tuberculous meningitis (TBM) in HIV-positive patients and comparing these parameters with those of extrapulmonary TB (TBEP) and pulmonary TB (TBP).Methods.Kaplan-Meier estimation and Poisson regression models were used to assess the mortality following TB diagnosis and to evaluate potential prognostic factors for the 3 groups of TB patients separately.Results.A total of 100 patients with TBM, 601 with TBEP, and 371 TBP were included. Patients with TBM had lower CD4 cell counts and only 17.0% received antiretroviral therapy (ART) at TB diagnosis. The cumulative probability of death at 12 months following TB was 51.2% for TBM (95% CI 41.4–61.6%), 12.3% for TBP (8.9–15.7%), and 19.4% for TBEP (16.1–22.6) (P<0.0001; log-rank test). For TBM, factors associated with a poorer prognosis were not being on ART (adjusted incidence rate ratio (aIRR) 4.00 (1.72–9.09), a prior AIDS diagnosis (aIRR=4.82(2.61–8.92)), and receiving care in Eastern Europe (aIRR=5.41(2.58–11.34))).Conclusions.TBM among HIV-positive patients was associated with a high mortality rate, especially for patients from Eastern Europe and patients with advanced HIV-infection, which urgently calls for public health interventions to improve both TB and HIV aspects of patient management.

Published
2013
Full Text
View/download PDF

47. The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool

Author

Revell, Ad, Wang, D, Boyd, Ma, Emery, S, Pozniak, Al, De Wolf, F, Harrigan, R, Montaner, Js, Lane, C, Larder, Ba, Collaborators: De Wolf F, RDI Study G. r. o. u. p., Lange, J, Montaner, J, Agan, B, Marconi, V, Wegner, S, Sugiura, W, Zazzi, M, Gatell, J, Lazzari, E, Gazzard, B, Nelson, M, Pozniak, A, Mandalia, S, Ruiz, L, Clotet, B, Staszewski, S, Torti, Carlo, Metcalf, J, Perez Elias MJ, Carr, A, Norris, R, Hesse, K, Vlahakis, E, Fist, E, Cooper, D, Torti, C, Baxter, J, Monno, L, Picchio, G, de Bethune MP, and Perez Elias, M. J.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results